Publications by authors named "Jill Denning"

Claim this Profile
S
Safety and efficacy of rodatristat ethyl for the treatment of pulmonary arterial hypertension (ELEVATE-2): a dose-ranging, randomised, multicentre, phase 2b trial.
Olivier Sitbon, Andris Skride, Jeremy Feldman, Sandeep Sahay, Oksana A Shlobin, Jill Denning

Lancet Respir Med· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A trial design to maximize knowledge of the effects of rodatristat ethyl in the treatment of pulmonary arterial hypertension (ELEVATE 2).
Howard M Lazarus, Jill Denning, Stephen Wring, Michelle Palacios, Sidra Hoffman

Pulm Circ· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
On-treatment HCV RNA in patients with varying degrees of fibrosis and cirrhosis in the SOLAR-1 trial.
Tania M Welzel, K Rajender Reddy, Steven L Flamm, Jill Denning, Ming Lin

Antivir Ther· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hepatitis C Virus RNA Persists in Liver Explants of Most Patients Awaiting Liver Transplantation Treated With an Interferon-Free Regimen.
Martina Gambato, Sofía Pérez-Del-Pulgar, Charlotte Hedskog, Evguenia S Svarovskia, Diana Brainard, Jill Denning

Gastroenterology· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial.
Michael Manns, Didier Samuel, Edward J Gane, David Mutimer, Geoff McCaughan, Jill Denning

Lancet Infect Dis· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease.
Michael Charlton, Gregory T Everson, Steven L Flamm, Princy Kumar, Charles Landis, Jill Denning

Gastroenterology· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation.
Xavier Forns, Michael Charlton, Jill Denning, John G McHutchison, William T Symonds

Hepatology· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study.
Michael P Curry, Xavier Forns, Raymond T Chung, Norah A Terrault, Robert Brown, Jill Denning

Gastroenterology· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation.
Michael Charlton, Edward Gane, Michael P Manns, Robert S Brown, Michael P Curry, Jill Denning

Gastroenterology· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of hepatitis C viral kinetics during administration of two nucleotide analogues: sofosbuvir (GS-7977) and GS-0938.
Jeremie Guedj, Phillip S Pang, Jill Denning, Maribel Rodriguez-Torres, Eric Lawitz

Antivir Ther· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, safety, and tolerability of GS-9851, a nucleotide analog polymerase inhibitor for hepatitis C virus, following single ascending doses in healthy subjects.
Jill Denning, Melanie Cornpropst, Stephen D Flach, Michelle M Berrey, William T Symonds

Antimicrob Agents Chemother· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, pharmacodynamics, and tolerability of GS-9851, a nucleotide analog polymerase inhibitor, following multiple ascending doses in patients with chronic hepatitis C infection.
Eric Lawitz, Maribel Rodriguez-Torres, Jill M Denning, Efsevia Albanis, Melanie Cornpropst

Antimicrob Agents Chemother· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis